Table 3B.
Efficacy findings in clinical trials in patients with ankylosing spondylitis.
| Author (Year) | Start / end time | Groups (Patients allocated) |
ASAS20 n(%) | ASAS40 n(%) | ASAS PR n(%) | BASDAI (mean) | BASFI (mean) | ASDAS Global Score (mean) | BASMI (mean) |
|---|---|---|---|---|---|---|---|---|---|
| Park et al.(2017) | Exchange: Week 54 | CT-P13/CT-P13 (n=88) |
End: 67/83 (80.7) | End: 53/83 (63.9) | End: 16/83 (19.3) | End: 3.19 | End: 3.24 | End: 1.86 | End: 2.4 |
|
End:
Week 102 |
INF/CT-P13 (n=86) |
End: 60/78 (76.9) | End: 48/78 (61.5) | End: 18/78 (23.1) | End: 3.23 | End: 3.25 | End: 1.97 | End: 2.6 | |
| Estimated p value | 0.506 | 0.672 | 0.275 | NS* | NS* | NS* | NS* |
ASAS, The Assessment of Spondylarthritis International Society; PR, Partial Remission; BASDAI, The Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASMI, Bath Ankylosing Spondylitis Metrology Index; ASDAS, Ankylosing Spondylitis Disease Activity Score.
* Standard deviation was not reported. Authors only compared graphically.